CompanyOTCToronto
Medicenna Therapeutics Corp
Medicenna is a clinical-stage immunotherapy company developing selective IL-2, IL-4, and IL-13 Superkines for cancer.
10-QAug 12Latest SEC filing, period to Jun 30
Form DJul 6$253K sold
July 2026
Sign inSign inMedicenna is a clinical-stage immunotherapy company developing selective IL-2, IL-4, and IL-13 Superkines for cancer.